TP53 abnormalities in CLL are linked to poor survival and therapeutic resistance, underscoring the importance of testing for TP53 deletions and mutations prior to initiating treatment, as this can guide clinical decision-making [100,101,102]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.